Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global spending on obesity medications, estimated at $24 billion in 2023, is projected to reach $131 billion by 2028. This 27% annual growth estimate is a significant increase from the previous projection of 13%. However, the actual figure could be even higher if insurance coverage expands.The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to the growing availability of weight-loss medications from Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY).
到2030年代初，全球減肥藥物市場預計將達到驚人的1500億美元，比先前預測的1000億美元大幅增長。這種激增歸因於諾和諾德（紐約證券交易所代碼：NVO）和禮來公司（紐約證券交易所代碼：LLY）的減肥藥物供應量增加。
What Happened: The sales of weight-loss drugs from Novo Nordisk and Eli Lilly are on the rise, as per a Reuters report. The increased supply, coupled with a surge in demand and the emergence of new competitors, has led industry experts to revise their sales forecasts.
發生了什麼：據路透社報道，諾和諾德和禮來公司的減肥藥物的銷量正在上升。供應的增加，加上需求的激增和新的競爭對手的出現，促使行業專家修改了他們的銷售預測。
Michael Kleinrock, a senior research director at healthcare analytics firm IQVIA Institute for Data Science, noted that the medications are capturing the attention of millions of people. Despite most insurers not covering these therapies with low co-payments, a significant number of individuals are paying for them out of pocket or using coupons from the drug manufacturers.
醫療分析公司IQVIA數據科學研究所的高級研究董事邁克爾·克萊因洛克指出，這些藥物吸引了數百萬人的注意。儘管大多數保險公司沒有以較低的自付額爲這些療法提供保障，但仍有相當數量的人是自掏腰包或使用藥品製造商的優惠券來支付這些療法。
The global spending on obesity medications, estimated at $24 billion in 2023, is projected to reach $131 billion by 2028. This 27% annual growth estimate is a significant increase from the previous projection of 13%. However, the actual figure could be even higher if insurance coverage expands.
全球肥胖藥物支出在2023年估計爲240億美元，預計到2028年將達到1310億美元。27％的年增長率估計比之前預測的13％大幅增加。但是，如果擴大保險覆蓋範圍，實際數字可能會更高。
"There's consumer demand and the unmet medical need. A 100 million plus Americans are obese, and even more are overweight. Worldwide, there are estimates out there of close to a billion who are obese," said David Song, portfolio manager of the Tema Obesity & Cardiometabolic ETF (NASDAQ:HRTS)
“有消費者需求和未滿足的醫療需求。超過1億的美國人肥胖，甚至更多的人超重。據估計，全球有近十億肥胖人士。” Tema肥胖與心臟代謝ETF（納斯達克股票代碼：HRTS）的投資組合經理戴維·宋說
Why It Matters: The weight-loss drug market has been a topic of much discussion recently. Novo Nordisk has been under scrutiny for the high prices of its drugs, including Ozempic and Wegovy, and its increasing influence on Denmark's employment has raised economic concerns.
爲何重要：減肥藥物市場最近一直是許多討論的話題。諾和諾德因其藥品（包括Ozempic和Wegovy）的高昂價格而受到審查，其對丹麥就業的影響越來越大，引發了經濟擔憂。
On the other hand, Elon Musk has predicted that Ozempic will become more affordable after a comedy special painted it as a weight-loss drug only the wealthy can afford. Additionally, Australia has banned replica versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly due to safety concerns.
另一方面，埃隆·馬斯克曾預測，Ozempic將變得更加實惠，此前一部喜劇特別節目將其描繪成只有富人才能負擔得起的減肥藥物。此外，出於安全考慮，澳大利亞已禁止Novo Nordisk和Eli Lilly生產流行的減肥藥物的仿製版本。
Image Via Pixabay
圖片來自 Pixabay
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
這個故事是使用 Benzinga Neuro 創作的，由 Kaustubh Bagalkote
譯文內容由第三人軟體翻譯。
